Beta blockers theoretically benefit coronary artery disease
by reducing myocardial demand and reducing potential for ischemia and arrhythmia. This has been demonstrated conclusively with
certain beta blockers (eg. Carvedilol).
Other beta blockers, like Metoprolol have not been conclusively shown to
reduce mortality and recurrent events, but most regard beta blocker benefits as
a class effect.
POSTED BY: Steven
Ajluni, MD
No comments:
Post a Comment